Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Epididymo-orchitis occurs as a complication in the course of mumps in 18% to 43% of postpubertal males.1-4 Not only is gonadal involvement accompanied by severe local pain and systemic discomfort, but testicular atrophy is a sequel in about one-half of the cases, and sterility can result, although this is probably unusual.5,6 Of the various prophylactic measures that have been tried in males with epidemic parotitis, the administration of diethylstilbestrol has given encouraging results,7,8 and early injection of \g=g\-globulinprepared from mumps convalescent serum has resulted in definite reduction in the incidence of orchitis.9 The treatment of established orchitis, however, has remained unsatisfactory. Antibiotics,10-14 pooled plasma,15-17 convalescent serum,18 estrogens,7 and surgical decompression [19][20][21] have been irregularly effective. At present, the usual regimen consists of analgesic and antipyretic drugs with local application of cold and the use of various suspensory devices.The few available descriptions of the his¬ tologie characteristics of mumps orchitis20 indicate that distention of seminiferous tubules by inflammatory exúdate, edema of intertubular connective tissue, swelling of the tunica albugínea, and acute hydrocele22 combine to produce pressure necrosis of the gonad. This supports the clinical impres-sion that swelling of the testicle within its unyielding tunics is the major factor respon¬ sible for acute pain and subsequent atrophie changes. This concept, of course, is the rationale for surgical decompression.The remarkable anti-inflammatory proper¬ ties of the adrenal steroids as well as their efficacy in alleviating a variety of "febrile toxemic" states suggested that these hor¬ mones might be useful in the management of mumps orchitis. The present report sum¬ marizes our experience with the use of cortisone and related compounds in the treat¬ ment of 23 cases of mumps orchitis during the past four years. Clinical MaterialThe 23 patients with mumps orchitis that form the basis of this report were observed during a period of four years on the They ranged in age from 13 to 44 years. All cases were sporadic ; no true epi¬ demic occurred during the period of study. In none of the hospitals where the study was carried out is it customary to admit patients with uncom¬ plicated epidemic parotitis.Examinations of cerebrospinal fluid, liver func¬ tion tests, serum amylase determinations, and mumps complement-fixation tests were carried out in several, but not all, patients. The results of adrenal steroid therapy were noted and recorded carefully during the acute dis¬ ease. Later follow-up examinations were possible in only 14 cases. There was considerable variation in dosage of hormones in individual cases during the period of the study, depending upon several factors, including availability of drugs, expense, and response to treatment.The pertinent data for the 23 cases are sum¬ marized in Table 1.
Epididymo-orchitis occurs as a complication in the course of mumps in 18% to 43% of postpubertal males.1-4 Not only is gonadal involvement accompanied by severe local pain and systemic discomfort, but testicular atrophy is a sequel in about one-half of the cases, and sterility can result, although this is probably unusual.5,6 Of the various prophylactic measures that have been tried in males with epidemic parotitis, the administration of diethylstilbestrol has given encouraging results,7,8 and early injection of \g=g\-globulinprepared from mumps convalescent serum has resulted in definite reduction in the incidence of orchitis.9 The treatment of established orchitis, however, has remained unsatisfactory. Antibiotics,10-14 pooled plasma,15-17 convalescent serum,18 estrogens,7 and surgical decompression [19][20][21] have been irregularly effective. At present, the usual regimen consists of analgesic and antipyretic drugs with local application of cold and the use of various suspensory devices.The few available descriptions of the his¬ tologie characteristics of mumps orchitis20 indicate that distention of seminiferous tubules by inflammatory exúdate, edema of intertubular connective tissue, swelling of the tunica albugínea, and acute hydrocele22 combine to produce pressure necrosis of the gonad. This supports the clinical impres-sion that swelling of the testicle within its unyielding tunics is the major factor respon¬ sible for acute pain and subsequent atrophie changes. This concept, of course, is the rationale for surgical decompression.The remarkable anti-inflammatory proper¬ ties of the adrenal steroids as well as their efficacy in alleviating a variety of "febrile toxemic" states suggested that these hor¬ mones might be useful in the management of mumps orchitis. The present report sum¬ marizes our experience with the use of cortisone and related compounds in the treat¬ ment of 23 cases of mumps orchitis during the past four years. Clinical MaterialThe 23 patients with mumps orchitis that form the basis of this report were observed during a period of four years on the They ranged in age from 13 to 44 years. All cases were sporadic ; no true epi¬ demic occurred during the period of study. In none of the hospitals where the study was carried out is it customary to admit patients with uncom¬ plicated epidemic parotitis.Examinations of cerebrospinal fluid, liver func¬ tion tests, serum amylase determinations, and mumps complement-fixation tests were carried out in several, but not all, patients. The results of adrenal steroid therapy were noted and recorded carefully during the acute dis¬ ease. Later follow-up examinations were possible in only 14 cases. There was considerable variation in dosage of hormones in individual cases during the period of the study, depending upon several factors, including availability of drugs, expense, and response to treatment.The pertinent data for the 23 cases are sum¬ marized in Table 1.
AFTER THE appearance of preliminary reports of favorable effects of aureomycin, chloramphenicol, and oxytetracycline ("terramycin") in mumps, these three broad-spectrum antibiotics were studied systematically for symptomatic effects when given early in the course of mumps orchitis. A clear demonstration of therapeutic results was considered desirable because epidemic parotitis was the most frequent infection of known viral etiology in a medical service for adults and was. often associated with distressing symptoms. Mumps orchitis was found to present a course severe enough and consistent enough to allow conclusions to be drawn from a few cases in which the symptoms persisted despite therapy. LITERATURE Aureomycin.\p=m-\Tentativereports of favorable results of aureomycin therapy in mumps were made by four groups of investigators. Langley and Bryfogle 1 treated three patients with parotitis on the first, third, and seventh days of illness with symptomatic improvement four, five, and two days, respectively, after treatment was begun. Schmuttermeier, Swoboda, and Thalhammer2 treated one patient with parotitis and bilateral orchitis with aureomycin on the seventh day of disease. The treatment was begun four days after the onset of left orchitis and on the day of onset of right orchitis. Both swellings disappeared in two more days. Spinelli, Cressy, and Kunkel3 treated four patients with mumps orchitis on the second, first, fourth and seventh days, respectively, with disappearance of fever and symp¬ toms in 32 to 36 hours after therapy in all. Testicular swelling disappeared within three days. Schaub 4 reported 11 cases of parotitis in adults treated with aureomycin, Dr. Barnes is now at the United States Naval Hospital, Jacksonville, Fla.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.